# Shasqi

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shasqi

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.shasqi.com
- Total disclosed funding: $10M
- Latest round: Series A (Oct 31, 2019)
- Investors on record: 1

## About

Shasqi, Inc. is a biotechnology company specializing in innovative cancer therapies. Utilizing their proprietary Click Activated Protodrugs Against Cancer (CAPAC®) platform, they enhance targeted drug delivery to tumors while minimizing normal tissue exposure.Founded in 2015 and headquartered in San Francisco, US, Shasqi, Inc. develops specialized cancer treatment solutions. The company has successfully closed 3 deals, with their most recent funding round being a Series B in November 2021, raising USD 50.00 mn, bringing the total amount raised to USD 50.00 mn. The company is led by José Oneto, who serves as both the CEO and the Founder.Shasqi, Inc. focuses on developing innovative cancer therapies through its proprietary Click Activated Protodrugs Against Cancer (CAPAC®) platform. This platform employs a pre-targeting approach utilizing in vivo click chemistry to enhance drug delivery specifically to tumors while minimizing exposure to normal tissues. The core functionality of CAPAC involves the separation of a clickable binder from a clickable payload, which reunites at the tumor site. This technology facilitates the selective binding of the payload, which can either be a radioisotope or an inert cancer drug, activating the treatment only upon interaction with the tumor-specific binder. Shasqi's products are designed to improve the therapeutic window of antibody-drug conjugates (ADCs) and targeted radiopharmaceuticals, with applications primarily in the oncology sector, serving healthcare providers and patients in markets including North America and Europe.Shasqi generates revenue through collaborations and partnerships within the biopharmaceutical sector, aligning with healthcare providers and research institutions focused on cancer treatment. The company engages in contractual agreements to provide its CAPAC platform for clinical development and commercialization of therapies tailored to specific cancer indications. These transactions include milestone payments and royalties, as well as potential licensing arrangements for its proprietary technology. Specific pricing details for its products and services are not publicly disclosed, but the focus remains on delivering effective and targeted cancer therapies to healthcare providers, thereby aiming to improve patient outcomes in an evolving oncology landscape.Shasqi, Inc. plans to utilize the USD 50.00 mn raised in Series B funding to advance the Phase 1/2 clinical study of SQ3370 for the treatment of injectable, advanced solid tumors. Additionally, the funding will support efforts to expand their click chemistry platform, enabling the development of therapeutics that do not require intratumoral injections. The company aims to target new markets for its innovative cancer therapies, further broadening its reach in the oncology sector.

## Funding rounds

- Series A, Oct 31, 2019, $10M — Y Combinator

## Investors

- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Series A